Search

Your search keyword '"Kumthekar, Priya"' showing total 562 results

Search Constraints

Start Over You searched for: Author "Kumthekar, Priya" Remove constraint Author: "Kumthekar, Priya"
562 results on '"Kumthekar, Priya"'

Search Results

Catalog

Books, media, physical & digital resources

4. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

5. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

7. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.

8. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

10. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

11. CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL

13. Stalking the Diagnosis

14. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.

15. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma

18. A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases

21. Clinical outcomes for pleomorphic xanthoastrocytoma patients.

22. A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy

23. Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.

27. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

28. ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA

29. Mutant IDH1 and seizures in patients with glioma

30. Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial

32. Sarcoma and the nervous system

33. Contributors

34. Diagnostics and Screening in Breast Cancer with Brain and Leptomeningeal Metastasis: A Review of the Literature.

35. Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.

38. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

39. Leptomeningeal Metastases from Solid Tumors : A Society for Neuro-Oncology and American Society of Clinical Oncology Consensus Review on Clinical Management and Future Directions

40. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer

41. A Multi-institutional Phase I Study of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT-methylated Malignant Glioma

42. Contributors List

44. CTNI-06. RHENIUM (RE-186) OBISBEMEDA{RE-186-NANOLIPOSOME (186RNL)} IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL: INITIAL SAFETY AND FEASIBILITY

45. CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL

47. CTNI-73. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS

48. RADT-43. LONG TERM OUTCOMES OF PEDIATRIC AND ADULT CENTRAL NEUROCYTOMA—THE ROLE OF SALVAGE RADIOTHERAPY AND CONSERVATIVE MANAGEMENT

50. CTIM-14. PHASE 1 SAFETY LEAD-IN AND RANDOMIZED OPEN-LABEL PERIOPERATIVE STUDY OF VORASIDENIB COMBINED WITH PEMBROLIZUMAB IN RECURRENT OR PROGRESSIVE ENHANCING IDH1-MUTANT ASTROCYTOMAS: SAFETY LEAD-IN RESULTS